Impact of 6% hydroxyethyl starch 130/0.42 and 4% gelatin on renal function in a pediatric animal model

Paediatric Anaesthesia

Volumn 24, Issue 9, 2014, Pages 974-979

  Witt, Lars ^a   Glage, Silke ^a   Schulz, Katharina ^a   Lichtinghagen, Ralf ^a   Simann, Arne ^b   Pape, Lars ^a   Sümpelmann, Robert ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Klinikum Region Hannover   (Germany)

Author keywords

colloids; gelatin; hydroxyethyl starch; i.v. infusions; pediatric anesthesia; renal function; renal parameters

Indexed keywords

CREATININE; CYSTATIN C; ELECTROLYTE; GELATIN; HETASTARCH; INFUSION FLUID; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; UREA; HETASTARCH DERIVATIVE; PLASMA SUBSTITUTE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; BLOOD LEVEL; COLLOID; CONTROLLED STUDY; FEMALE; HISTOLOGY; INFLAMMATION; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; KIDNEY TUBULE NECROSIS; NONHUMAN; PEDIATRIC ANESTHESIA; PIGLET; PRIORITY JOURNAL; RISK ASSESSMENT; URINALYSIS; ANIMAL; BLOOD; DRUG EFFECTS; KIDNEY; PIG; STATISTICS AND NUMERICAL DATA; URINE;

ANIMALS; FEMALE; GELATIN; HYDROXYETHYL STARCH DERIVATIVES; KIDNEY; KIDNEY FUNCTION TESTS; MODELS, ANIMAL; PLASMA SUBSTITUTES; SWINE;

EID: 84905637867     PISSN: 11555645     EISSN: 14609592     Source Type: Journal    
DOI: 10.1111/pan.12445     Document Type: Article

References (20)

1. Saudan S,. Is the use of colloids for fluid replacement harmless in children? Curr Opin Anaesthesiol 2010; 23: 363-367.
2. Brunkhorst FM, Engel C, Bloos F, et al,. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358: 125-139.
3. Mutter TC, Ruth CA, Dart AB,. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 2013; 7: CD007594.
4. Perner A, Haase N, Guttormsen AB, et al,. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012; 367: 124-134.
5. Myburgh JA, Finfer S, Bellomo R, et al,. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012; 367: 1901-1911.
6. PRAC recommends suspending marketing authorisations for infusion solutions containing hydroxyethyl-starch. Available at: http://www.ema.europa. eu/docs/en-GB/document-library/Referrals-document/Solutions-for-infusion- containing-hydroxyethyl-starch/Recommendation-provided-by-Pharmacovigilance- Risk-Assessment-Committee/WC500144448.pdf. Accessed 20 December, 2013.
7. Hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients-CMDh endorses PRAC recommendation. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/Press-release/2013/10/WC500153125.pdf. Accessed 20 December, 2013.
8. Sümpelmann R, Kretz FJ, Luntzer R, et al,. Hydroxyethyl starch 130/0.42/6:1 for perioperative plasma volume replacement in 1130 children: results of an European prospective multicenter observational postauthorization safety study (PASS). Pediatr Anesth 2012; 22: 371-378.
9. Van Der Linden P, James M, Mythen M, et al,. Safety of modern starches used during surgery. Anesth Analg 2013; 116: 35-48.
10. Thomas-Rueddel DO, Vlasakov V, Reinhart K, et al,. Safety of gelatin for volume resuscitation-a systematic review and meta-analysis. Intensive Care Med 2012; 38: 1134-1142.
11. Witt L, Osthaus WA, Lucke T, et al,. Safety of glucose-containing solutions during accidental hyperinfusion in piglets. Br J Anaesth 2010; 105: 635-639.
12. Kashani K, Al-Khafaji A, Ardiles T, et al,. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care 2013; 17: R25.
13. Hüter L, Simon TP, Weinmann L, et al,. Hydroxyethylstarch impairs renal function and induces interstitial proliferation, macrophage infiltration and tubular damage in an isolated renal perfusion model. Crit Care 2009; 13: R23.
14. Simon TP, Schuerholz T, Huter L, et al,. Impairment of renal function using hyperoncotic colloids in a two hit model of shock: a prospective randomized study. Crit Care 2012; 16: R16.
15. Unger V, Grosse-Siestrup C, Fehrenberg C, et al,. Reference values and physiological characterization of a specific isolated pig kidney perfusion model. J Occup Med Toxicol 2007; 2: 1.
16. Akkucuk FG, Kanbak M, Ayhan B, et al,. The effect of HES (130/0.4) usage as the priming solution on renal function in children undergoing cardiac surgery. Ren Fail 2013; 35: 210-215.
17. Hanart C, Khalife M, De Ville A, et al,. Perioperative volume replacement in children undergoing cardiac surgery: albumin versus hydroxyethyl starch 130/0.4. Crit Care Med 2009; 37: 696-701.
18. Van der Linden P, De Ville A, Hofer A, et al,. Six percent hydroxyethyl starch 130/0.4 (voluven(R)) versus 5% human serum albumin for volume replacement therapy during elective open-heart surgery in pediatric patients. Anesthesiology 2013; 119: 1296-1309.
19. Silberstein JL, Sprenkle PC, Su D, et al,. Neutrophil gelatinase-associated lipocalin (NGAL) levels in response to unilateral renal ischaemia in a novel pilot two-kidney porcine model. BJU Int 2013; 112: 517-525.
20. Jochmans I, Lerut E, van Pelt J, et al,. Circulating AST, H-FABP, and NGAL are early and accurate biomarkers of graft injury and dysfunction in a preclinical model of kidney transplantation. Ann Surg 2011; 254: 784-791.